Loading clinical trials...
Loading clinical trials...
Assessment of the Efficacy and Safety of Molindone Hydrochloride Extended-Release for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder in Conjunction With Standard ADHD Treatment
Conditions
Interventions
SPN-810 (18 mg)
SPN-810 (36 mg)
+1 more
Locations
32
United States
Metropolitan Neuro Behavioral Institute
Chandler, Arizona, United States
Woodland International Research Group
Little Rock, Arkansas, United States
Sun Valley Research Center
Imperial, California, United States
Alliance for Wellness dba Alliance for Research
Long Beach, California, United States
ASCLEPES Research Center
Panorama City, California, United States
MCB Clinical Research Centers, LLC
Colorado Springs, Colorado, United States
Start Date
February 16, 2016
Primary Completion Date
November 15, 2019
Completion Date
February 14, 2020
Last Updated
March 18, 2024
NCT07189442
NCT07459699
NCT07165509
NCT07121621
NCT06170996
NCT05137704
Lead Sponsor
Supernus Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions